Paper Details
- Home
- Paper Details
Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG.
Author: BeltranS, EdemP, HizS, HorvathR, LaurieS, LochmullerH, O'HeirE, OktayY, PaketciC, Sarikaya UzanG, SonmezlerE, SoydemirD, TöpfA, YisU
Original Abstract of the Article :
BACKGROUND: Congenital disorders of glycosylation (CDG) is a heterogeneous group of congenital metabolic diseases with multisystem clinical involvement. ALG3-CDG is a very rare subtype with only 24 cases reported so far. CASE: Here, we report two siblings with dysmorphic features, growth retardatio...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/32389449
データ提供:米国国立医学図書館(NLM)
A Promising Treatment for a Rare Genetic Condition
This research delves into the complex world of congenital disorders of glycosylation (CDG), a group of genetic conditions that disrupt the body's ability to create crucial sugars. It focuses on a particular subtype, ALG3-CDG, which is incredibly rare, with only 24 cases documented so far. The study examined two siblings who presented with a unique combination of symptoms, including growth delays, microcephaly (smaller than average head size), intractable epilepsy, and unusual growths called hemangiomas.The researchers used a technique called whole exome sequencing to analyze the siblings' genes, revealing a previously identified genetic variant in the ALG3 gene associated with ALG3-CDG. This variant disrupts the normal functioning of the ALG3 gene, leading to the observed symptoms. Notably, the researchers found that the siblings' epilepsy, which had been unresponsive to conventional treatments, was effectively controlled through a ketogenic diet. This groundbreaking discovery suggests that a ketogenic diet could be a potential treatment option for epilepsy in patients with ALG3-CDG.
Ketogenic Diet: A Potential Solution for Intractable Epilepsy in ALG3-CDG
The finding that a ketogenic diet can successfully control epilepsy in ALG3-CDG is truly remarkable. This suggests that this dietary approach may offer a viable treatment option for individuals with this rare condition. The study's findings provide much-needed hope for patients and their families, offering the potential for improved quality of life.Hope on the Horizon: A New Treatment Pathway for a Rare Disease
The success of the ketogenic diet in treating intractable epilepsy in these siblings underscores the importance of personalized medicine. Think of it this way: Just as a camel thrives in the harsh desert environment with its unique adaptations, each individual with ALG3-CDG may require a customized approach to effectively manage their condition. This discovery sheds light on the potential benefits of the ketogenic diet in treating neurological disorders and opens up new avenues for future research in the field of rare diseases.Dr.Camel's Conclusion
This study provides a beacon of hope for those struggling with ALG3-CDG, a rare and complex condition. By uncovering the potential of the ketogenic diet in managing intractable epilepsy, the researchers have unearthed a new pathway for treatment. It serves as a reminder that even in the vast and challenging landscape of rare diseases, solutions can be found through persistent research and a focus on personalized care.Date :
- Date Completed 2021-03-08
- Date Revised 2022-12-07
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.